Joshua Schimmer

Stock Analyst at Cantor Fitzgerald

(1.37)
# 3,566
Out of 5,044 analysts
23
Total ratings
56.25%
Success rate
-6.96%
Average return

Stocks Rated by Joshua Schimmer

Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.79
Upside: +1,692.11%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $71.65
Upside: -30.22%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91$92
Current: $92.05
Upside: -0.05%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $70.00
Upside: -71.43%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $148.94
Upside: -12.72%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80$50
Current: $16.21
Upside: +208.45%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16$25
Current: $33.69
Upside: -25.79%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65$75
Current: $3.94
Upside: +1,803.55%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90$100
Current: $52.67
Upside: +89.86%
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $585.31
Upside: -
Assumes: Overweight
Price Target: $85
Current: $93.08
Upside: -8.68%